CD8A and neoplasm: By demonstrating that the immunosuppressive PDAC TME can be transformed into an immunogenic TME with increased numbers of tumor‐antigen specific and unexhausted CD8+ T‐cells, combination therapy shows its potential in increasing the sensitivity of PDAC to different types of immune checkpoint inhibitors (ICIs).